Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6877661 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| Hydrochloric Acid SCHEMBL7936029 | 0.97 | ALDH1A1 (0.50) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL7627478 | 0.97 | ALDH1A1 (0.50) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL6290733 | 0.93 | ALDH1A1 (0.47) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL6273763 | 0.91 | ALDH1A1 (0.46) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| Formic Acid SCHEMBL20660413 | 0.91 | ALDH1A1 (0.46) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| Amantadine SCHEMBL8710832 | 0.89 | LMNA (0.56) | ALDH1A1HTTCRHBPCRHR2MCOLN3 | |
| SCHEMBL16038530 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL31074189 | 0.86 | — | — | |
| Trifluoroacetic Acid SCHEMBL6384678 | 0.85 | ALDH1A1 (0.42) | ALDH1A1HTTCRHBPCRHR2MCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367144-A1 | TREATMENT OF HYPERINFLAMMATORY SYNDROME | REMICINE IP B V (NL) | 2025-12-04 | — | — | US | claimed |
| US-12419848-B2 | Treatment of hyperinflammatory syndrome | Remicine IP B.V. (NL) | 2025-09-23 | — | — | US | claimed |
| CN-118748993-A | Indazole compounds and medicaments | 日本新药株式会社 | 2024-10-08 | — | — | CN | claimed |
| CN-118666703-A | Preparation method of 1-adamantane formamide | 浙江荣耀生物科技股份有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118561899-A | Adamantane formamide piperazine axial substituted silicon phthalocyanine and preparation method and application thereof | 福建师范大学 | 2024-08-30 | — | — | CN | claimed |
| EP-4324832-A2 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-113582980-B | Compound based on heterocyclic ring and glutarimide skeleton and application thereof | 上海科技大学 | 2023-11-24 | — | — | CN | claimed |
| US-20230355749-A1 | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | AC BIOSCIENCE SA (CH) | 2023-11-09 | — | — | US | claimed |
| EP-4216997-A1 | IMMUNOMODULATORY COMPOUNDS AND USE THEREOF FOR THE TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES | AC BioScience SA (CH) | 2023-08-02 | — | — | EP | claimed |
| CN-113372327-B | Glutarimide skeleton-based compound and application thereof | 上海科技大学 | 2023-07-18 | — | — | CN | claimed |
| WO-1998027950-A1 | ANTIPERSPIRANT GEL-SOLID STICK COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1998-07-02 | — | — | WO | claimed |
| US-5750096-A | SOLID NON-POLYMERIC GELLANT BASED ON 12-HYDROXYSTEARIC ACID; ANHYDROUS LIQUID CARRIER | THE PROCTER & GAMBLE COMPANY (US) | 1998-05-12 | — | — | US | claimed |
| US-5744130-A | COMPRISING ACTIVE MATERIAL, NONPOLYMERIC GELLANT, ANHYDROUS LIQUID CARRIER; LOW RESIDUE | THE PROCTER & GAMBLE COMPANY (US) | 1998-04-28 | — | — | US | claimed |
| WO-1997015564-A1 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| US-5591424-A | Antiperspirant gel stick compositions | THE PROCTER & GAMBLE COMPANY (US) | 1997-01-07 | — | — | US | claimed |
| US-5429816-A | Hydroxystearic acid and n-acyl-glutamic acid as gellants | PROCTER & GAMBLE (US) | 1995-07-04 | — | — | US | claimed |
| US-5208228-A | Skin disorders | MERCK & CO., INC. (US) | 1993-05-04 | — | — | US | claimed |
| EP-0322643-B1 | MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE | BAYER AG (DE) | 1991-07-24 | — | — | EP | claimed |
| EP-0428365-A1 | Aminomacrolides and derivatives having immunosuppressive activity | MERCK & CO. INC. (US) | 1991-05-22 | — | — | EP | claimed |
| US-4014892-A | ANTHELMINTICS | AMERICAN CYANAMID COMPANY (US) | 1977-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355749-A1 | Immunomodulatory Compounds And Use Thereof For The Treatment And/Or Prevention Of Infectious Diseases | CD14, TLR9, TLR3 | ALDH1A1 3963/4885HTT 3191/4885CRHBP 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.